Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 8;11(12):e007487. doi: 10.1136/jitc-2023-007487

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Disulfiram enhances the efficacy of immune checkpoint blockade therapy. (A) EMT6 tumor growth (left) and survival analysis (right) of mice treated with vehicle, disulfiram, anti-CTLA-4, or disulfiram+anti-CTLA-4. n=6 mice/group for tumor volume analysis; n=8 mice/group for survival analysis; two-way ANOVA for tumor volume comparison; log-rank test for survival comparison. (B) Quantification of CD8⁺ T cells ratios in EMT6 tumors treated with indicated treatments (n=5, one-way ANOVA). (C) B16-F10 tumor growth (left) and survival analysis (right) of mice treated with vehicle, disulfiram, anti-PD-1, or disulfiram+anti-PD-1. n=6 mice/group for tumor volume analysis; n=8 mice/group for survival analysis; two-way ANOVA for tumor volume comparison; log-rank test for survival comparison. (D) Quantification of CD8⁺ T cells ratios in B16-F10 tumors treated with indicated treatments (n=5, one-way ANOVA). (E–F) Representative flow cytometry images and percentages of IFN-γ⁺ CD8⁺ T cells from EMT6 (E) and B16-F10 (F) tumors (n=5, one-way ANOVA). Mean±SEM; *p<0.05; **p<0.01; ***p<0.001.